Pharmacy and Therapeutics Committee Agenda for October 14, 2005
The Pharmacy & Therapeutics Committee will meet Friday, October 14, 2005, from 10:30 a.m. to 3:00 p.m., in Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.
1. Proposal: To reimburse Risperdal Consta, with prior authorization, for selected, qualified mental health programs.
Description: The Committee will consider a proposal to allow Medicaid reimbursement, with prior authorization, for Risperdal Consta. This proposal applies only to qualified mental health outpatient programs, and is based on the recommendations of the Office of Mental Health.
Therapeutic Class: Atypical Antipsychotic
List of Drugs Affected: Risperdal Consta
2. Proposal: Prior authorization of Xyrem.
Description: The DOH is recommending that this drug, which has the potential for substantial misuse, be subject to prior authorization.
Therapeutic Class: Anti-narcolepsy & Anti-cataplexy, Sedative-type Agent
List of Drugs Affected: Xyrem
3. Proposal: Exemption of levothyroxine from the Mandatory Generic program requirements.
Description: The Committee will consider whether brand name levothyroxine sodium products should be exempted from the requirements of the Mandatory Generic program.
Therapeutic Class: Thyroid Hormones
List of Drugs Affected: Unithroid, Synthroid, Levoxcyl, Levo-T
10:30 - 10:40 Welcome and Introductions
10:40 - 11:40 Comments from interested parties*
11:40 - 1:00 Committee Discussion and Recommendations:
- Review the proposal to allow for prior authorization of risperidone injection in qualified programs
- Review of the proposal to require prior authorization of Xyrem
- Review of the proposal to exempt brand levothyroxine from the Mandatory Generic program
1:00 Adjournment of Public Session
1:00 - 1:30 Lunch Break
1:30 - 2:30 Executive Session: Orientation for Committee members on ethics requirements
2:30 Executive Session Adjourned
**Speakers must notify DOH at least 48 hours in advance of their intent to speak at the committee meeting. To get on the agenda, you may call 518-486-3209 or e-mail email@example.com (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, and must be brief. Written comments regarding topics before the Committee may also be submitted but must be received at least 48 hours in advance of the meeting. Written comments should summarize key points and may not exceed two pages in length. NOTE: Those wishing to submit a clinical study or clinical report, rather than comments, must submit the study at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review of this type of material. If such material is submitted after this time, it cannot be considered by the Committee.